Does This Pharma Company's Lead Asset Make it a Buy Today?

Bipolar disorder is relatively common, with 2.8% of adults, or 6 million Americans, reporting symptoms over a 12-month period. But the market is underserved; in particular, only a limited number of pharmaceutical companies have succeeded in launching treatments for bipolar-related depression. Hence, the recent clinical success of Intra-Cellular Therapies' (NASDAQ: ITCI) antipsychotic drug, lumateperone, in the treatment of bipolar-related depression is a noteworthy catalyst for investors.

But does this clinical success make Intra-Cellular Therapies a Buy? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com